Cargando…
Subcutaneous cladribine to treat multiple sclerosis: experience in 208 patients
OBJECTIVE: To report on safety and effectiveness of subcutaneous cladribine (Litak(®)) in multiple sclerosis (MS) patients. METHODS: Litak(®) was offered to MS-patients irrespective of disease course. Litak(®) 10 mg was administered for 3–4 days during week 1. Based on lymphocyte count at week 4, pa...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8842147/ https://www.ncbi.nlm.nih.gov/pubmed/35173808 http://dx.doi.org/10.1177/17562864211057661 |
_version_ | 1784650992801808384 |
---|---|
author | Allen-Philbey, Kimberley De Trane, Stefania Mao, Zhifeng Álvarez-González, Cesar Mathews, Joela MacDougall, Amy Stennett, Andrea Zhou, Xia Yildiz, Ozlem Adams, Ashok Bianchi, Lucia Blain, Camilla Chapman, Christine Chung, Karen Constantinescu, Cris S Dalton, Catherine Farrell, Rachel A Fisniku, Leonora Ford, Helen Gran, Bruno Hobart, Jeremy Khaleeli, Zhaleh Mattoscio, Miriam Pavitt, Sue Pearson, Owen Peruzzotti-Jametti, Luca Scalfari, Antonio Sharrack, Basil Silber, Eli Tallantyre, Emma C Webb, Stewart Turner, Benjamin P Marta, Monica Gnanapavan, Sharmilee Juliusson, Gunnar Giovannoni, Gavin Baker, David Schmierer, Klaus |
author_facet | Allen-Philbey, Kimberley De Trane, Stefania Mao, Zhifeng Álvarez-González, Cesar Mathews, Joela MacDougall, Amy Stennett, Andrea Zhou, Xia Yildiz, Ozlem Adams, Ashok Bianchi, Lucia Blain, Camilla Chapman, Christine Chung, Karen Constantinescu, Cris S Dalton, Catherine Farrell, Rachel A Fisniku, Leonora Ford, Helen Gran, Bruno Hobart, Jeremy Khaleeli, Zhaleh Mattoscio, Miriam Pavitt, Sue Pearson, Owen Peruzzotti-Jametti, Luca Scalfari, Antonio Sharrack, Basil Silber, Eli Tallantyre, Emma C Webb, Stewart Turner, Benjamin P Marta, Monica Gnanapavan, Sharmilee Juliusson, Gunnar Giovannoni, Gavin Baker, David Schmierer, Klaus |
author_sort | Allen-Philbey, Kimberley |
collection | PubMed |
description | OBJECTIVE: To report on safety and effectiveness of subcutaneous cladribine (Litak(®)) in multiple sclerosis (MS) patients. METHODS: Litak(®) was offered to MS-patients irrespective of disease course. Litak(®) 10 mg was administered for 3–4 days during week 1. Based on lymphocyte count at week 4, patients received another 0–3 doses at week 5. A second course was administered 11 months later. Follow-up included adverse events, relapses, expanded disability status scale (EDSS), 9-hole-peg and Timed-25-foot-walking tests, no-evidence-of-disease-activity (NEDA), no-evidence-of-progression-or-active-disease (NEPAD), MRI, cerebrospinal fluid (CSF) neurofilament light chain (NfL), and lymphocyte counts. RESULTS: In all, 208 patients received at least one course of treatment. Age at baseline was 44 (17–72) years and EDSS 0–8.5. Cladribine was generally well tolerated. One myocardial infarction, one breast cancer, and three severe skin reactions occurred without long-term sequelae. Two patients died (one pneumonia, one encephalitis). Lymphopenia grade 3 occurred in 5% and grade 4 in 0.5%. In 94 out of 116 pwMS with baseline and follow-up (BaFU) data after two treatment courses, EDSS remained stable or improved. At 18 months, 64% of patients with relapsing MS and BaFU data (n = 39) had NEDA. At 19 months, 62% of patients with progressive MS and BaFU data (n = 13) had NEPAD. Of n = 13 patients whose CSF-NfL at baseline was elevated, 77% were normalised within 12 months. CONCLUSIONS: Litak(®) was well tolerated. Effectiveness in relapsing MS appeared similar to cladribine tablets and was encouraging in progressive MS. Our data suggest cladribine may be safe and effective in MS-patients irrespective of their disease stage. |
format | Online Article Text |
id | pubmed-8842147 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-88421472022-02-15 Subcutaneous cladribine to treat multiple sclerosis: experience in 208 patients Allen-Philbey, Kimberley De Trane, Stefania Mao, Zhifeng Álvarez-González, Cesar Mathews, Joela MacDougall, Amy Stennett, Andrea Zhou, Xia Yildiz, Ozlem Adams, Ashok Bianchi, Lucia Blain, Camilla Chapman, Christine Chung, Karen Constantinescu, Cris S Dalton, Catherine Farrell, Rachel A Fisniku, Leonora Ford, Helen Gran, Bruno Hobart, Jeremy Khaleeli, Zhaleh Mattoscio, Miriam Pavitt, Sue Pearson, Owen Peruzzotti-Jametti, Luca Scalfari, Antonio Sharrack, Basil Silber, Eli Tallantyre, Emma C Webb, Stewart Turner, Benjamin P Marta, Monica Gnanapavan, Sharmilee Juliusson, Gunnar Giovannoni, Gavin Baker, David Schmierer, Klaus Ther Adv Neurol Disord Original Research OBJECTIVE: To report on safety and effectiveness of subcutaneous cladribine (Litak(®)) in multiple sclerosis (MS) patients. METHODS: Litak(®) was offered to MS-patients irrespective of disease course. Litak(®) 10 mg was administered for 3–4 days during week 1. Based on lymphocyte count at week 4, patients received another 0–3 doses at week 5. A second course was administered 11 months later. Follow-up included adverse events, relapses, expanded disability status scale (EDSS), 9-hole-peg and Timed-25-foot-walking tests, no-evidence-of-disease-activity (NEDA), no-evidence-of-progression-or-active-disease (NEPAD), MRI, cerebrospinal fluid (CSF) neurofilament light chain (NfL), and lymphocyte counts. RESULTS: In all, 208 patients received at least one course of treatment. Age at baseline was 44 (17–72) years and EDSS 0–8.5. Cladribine was generally well tolerated. One myocardial infarction, one breast cancer, and three severe skin reactions occurred without long-term sequelae. Two patients died (one pneumonia, one encephalitis). Lymphopenia grade 3 occurred in 5% and grade 4 in 0.5%. In 94 out of 116 pwMS with baseline and follow-up (BaFU) data after two treatment courses, EDSS remained stable or improved. At 18 months, 64% of patients with relapsing MS and BaFU data (n = 39) had NEDA. At 19 months, 62% of patients with progressive MS and BaFU data (n = 13) had NEPAD. Of n = 13 patients whose CSF-NfL at baseline was elevated, 77% were normalised within 12 months. CONCLUSIONS: Litak(®) was well tolerated. Effectiveness in relapsing MS appeared similar to cladribine tablets and was encouraging in progressive MS. Our data suggest cladribine may be safe and effective in MS-patients irrespective of their disease stage. SAGE Publications 2021-11-25 /pmc/articles/PMC8842147/ /pubmed/35173808 http://dx.doi.org/10.1177/17562864211057661 Text en © The Author(s), 2021 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Original Research Allen-Philbey, Kimberley De Trane, Stefania Mao, Zhifeng Álvarez-González, Cesar Mathews, Joela MacDougall, Amy Stennett, Andrea Zhou, Xia Yildiz, Ozlem Adams, Ashok Bianchi, Lucia Blain, Camilla Chapman, Christine Chung, Karen Constantinescu, Cris S Dalton, Catherine Farrell, Rachel A Fisniku, Leonora Ford, Helen Gran, Bruno Hobart, Jeremy Khaleeli, Zhaleh Mattoscio, Miriam Pavitt, Sue Pearson, Owen Peruzzotti-Jametti, Luca Scalfari, Antonio Sharrack, Basil Silber, Eli Tallantyre, Emma C Webb, Stewart Turner, Benjamin P Marta, Monica Gnanapavan, Sharmilee Juliusson, Gunnar Giovannoni, Gavin Baker, David Schmierer, Klaus Subcutaneous cladribine to treat multiple sclerosis: experience in 208 patients |
title | Subcutaneous cladribine to treat multiple sclerosis: experience in
208 patients |
title_full | Subcutaneous cladribine to treat multiple sclerosis: experience in
208 patients |
title_fullStr | Subcutaneous cladribine to treat multiple sclerosis: experience in
208 patients |
title_full_unstemmed | Subcutaneous cladribine to treat multiple sclerosis: experience in
208 patients |
title_short | Subcutaneous cladribine to treat multiple sclerosis: experience in
208 patients |
title_sort | subcutaneous cladribine to treat multiple sclerosis: experience in
208 patients |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8842147/ https://www.ncbi.nlm.nih.gov/pubmed/35173808 http://dx.doi.org/10.1177/17562864211057661 |
work_keys_str_mv | AT allenphilbeykimberley subcutaneouscladribinetotreatmultiplesclerosisexperiencein208patients AT detranestefania subcutaneouscladribinetotreatmultiplesclerosisexperiencein208patients AT maozhifeng subcutaneouscladribinetotreatmultiplesclerosisexperiencein208patients AT alvarezgonzalezcesar subcutaneouscladribinetotreatmultiplesclerosisexperiencein208patients AT mathewsjoela subcutaneouscladribinetotreatmultiplesclerosisexperiencein208patients AT macdougallamy subcutaneouscladribinetotreatmultiplesclerosisexperiencein208patients AT stennettandrea subcutaneouscladribinetotreatmultiplesclerosisexperiencein208patients AT zhouxia subcutaneouscladribinetotreatmultiplesclerosisexperiencein208patients AT yildizozlem subcutaneouscladribinetotreatmultiplesclerosisexperiencein208patients AT adamsashok subcutaneouscladribinetotreatmultiplesclerosisexperiencein208patients AT bianchilucia subcutaneouscladribinetotreatmultiplesclerosisexperiencein208patients AT blaincamilla subcutaneouscladribinetotreatmultiplesclerosisexperiencein208patients AT chapmanchristine subcutaneouscladribinetotreatmultiplesclerosisexperiencein208patients AT chungkaren subcutaneouscladribinetotreatmultiplesclerosisexperiencein208patients AT constantinescucriss subcutaneouscladribinetotreatmultiplesclerosisexperiencein208patients AT daltoncatherine subcutaneouscladribinetotreatmultiplesclerosisexperiencein208patients AT farrellrachela subcutaneouscladribinetotreatmultiplesclerosisexperiencein208patients AT fisnikuleonora subcutaneouscladribinetotreatmultiplesclerosisexperiencein208patients AT fordhelen subcutaneouscladribinetotreatmultiplesclerosisexperiencein208patients AT granbruno subcutaneouscladribinetotreatmultiplesclerosisexperiencein208patients AT hobartjeremy subcutaneouscladribinetotreatmultiplesclerosisexperiencein208patients AT khaleelizhaleh subcutaneouscladribinetotreatmultiplesclerosisexperiencein208patients AT mattosciomiriam subcutaneouscladribinetotreatmultiplesclerosisexperiencein208patients AT pavittsue subcutaneouscladribinetotreatmultiplesclerosisexperiencein208patients AT pearsonowen subcutaneouscladribinetotreatmultiplesclerosisexperiencein208patients AT peruzzottijamettiluca subcutaneouscladribinetotreatmultiplesclerosisexperiencein208patients AT scalfariantonio subcutaneouscladribinetotreatmultiplesclerosisexperiencein208patients AT sharrackbasil subcutaneouscladribinetotreatmultiplesclerosisexperiencein208patients AT silbereli subcutaneouscladribinetotreatmultiplesclerosisexperiencein208patients AT tallantyreemmac subcutaneouscladribinetotreatmultiplesclerosisexperiencein208patients AT webbstewart subcutaneouscladribinetotreatmultiplesclerosisexperiencein208patients AT turnerbenjaminp subcutaneouscladribinetotreatmultiplesclerosisexperiencein208patients AT martamonica subcutaneouscladribinetotreatmultiplesclerosisexperiencein208patients AT gnanapavansharmilee subcutaneouscladribinetotreatmultiplesclerosisexperiencein208patients AT juliussongunnar subcutaneouscladribinetotreatmultiplesclerosisexperiencein208patients AT giovannonigavin subcutaneouscladribinetotreatmultiplesclerosisexperiencein208patients AT bakerdavid subcutaneouscladribinetotreatmultiplesclerosisexperiencein208patients AT schmiererklaus subcutaneouscladribinetotreatmultiplesclerosisexperiencein208patients |